Abstract
The most common cause of false-positive PET is inflammation, whether infectious or otherwise. Recent local therapy, such as surgery or radiation, will produce inflammation that can persist for months. Surgery can produce reactive uptake in local soft tissues and nodes, and the interpreter should be aware of changes in highly active tissues (such as a neobladder). Radiation can produce intense uptake, but is often in a linear pattern. Granulomatous inflammation (autoimmune or infectious) can produce false positives due to its intensity and nodularity. Access to the patient history is thus useful. False negatives may be seen in high-background organs such as the brain (necessitating a brain MR for full staging) or kidneys and bladder. Muscle metastases may be difficult to detect on CT, whereas bone metastases may be only detectable on CT. Brown fat in the neck is intense but has a characteristic pattern that should be recognized. Lesions below a centimeter cannot be reliably detected, though they are sometimes visible. A variety of motion artifacts, most commonly due to musculoskeletal motion or breathing, can cause errors in attenuation correction and/or anatomic correlation. Non-attenuation-corrected images may be useful here. Sites at the border of the imaging field may be poorly visualized. Intense physiologic uptake may obscure uptake in nearby metastases. Incidental findings are relatively common, particularly in the thyroid and colon, and should be noted as they may represent another primary malignancy. Finally, incidental findings on CT such as pneumothorax may be important as well.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kumar R, Mavi A, Bural G, Alavi A. Fluorodeoxyglucose-PET in the management of malignant melanoma. Radiol Clin N Am. 2005;43(1):23–33.
Wallitt K, Yusuf S, Soneji N, Khan SR, Win Z, Barwick TD. PET/CT in oncologic imaging of nodal disease: pearls and pitfalls: RadioGraphics fundamentals | online presentation. Radiographics. 2018;38(2):564–5.
Lococo F, Muoio B, Chiappetta M, Nachira D, Petracca Ciavarella L, Margaritora S, et al. Diagnostic performance of PET or PET/CT with different radiotracers in patients with suspicious lung cancer or pleural tumours according to published meta-analyses. Contrast Media Mol Imaging. 2020;5282698:2020.
Bourgeois AC, Chang TT, Fish LM, Bradley YC. Positron emission tomography/computed tomography in melanoma. Radiol Clin N Am. 2013;51(5):865–79.
Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328–54.
Sachpekidis C, Kopp-Schneider A, Hakim-Meibodi L, Dimitrakopoulou-Strauss A, Hassel JC. 18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab. Melanoma Res. 2019;29(2):178–86.
Sachpekidis C, Larribere L, Kopp-Schneider A, Hassel JC, Dimitrakopoulou-Strauss A. Can benign lymphoid tissue changes in (18)F-FDG PET/CT predict response to immunotherapy in metastatic melanoma? Cancer Immunol Immunother. 2019;68(2):297–303.
Nobashi T, Baratto L, Reddy SA, Srinivas S, Toriihara A, Hatami N, et al. Predicting response to immunotherapy by evaluating tumors, lymphoid cell-rich organs, and immune-related adverse events using FDG-PET/CT. Clin Nucl Med. 2019;44(4):e272–9.
Lang N, Dick J, Slynko A, Schulz C, Dimitrakopoulou-Strauss A, Sachpekidis C, et al. Clinical significance of signs of autoimmune colitis in (18)F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients. Immunotherapy. 2019;11(8):667–76.
Goldfarb L, Duchemann B, Chouahnia K, Zelek L, Soussan M. Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST. EJNMMI Res. 2019;9(1):8.
Ito K, Teng R, Schoder H, Humm JL, Ni A, Michaud L, et al. (18)F-FDG PET/CT for monitoring of ipilimumab therapy in patients with metastatic melanoma. J Nucl Med. 2019;60(3):335–41.
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–52.
Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol. 2010;195(2):310–20.
Treglia G, Bertagna F, Sadeghi R, Muoio B, Giovanella L. Prevalence and risk of malignancy of focal incidental uptake detected by fluorine-18-fluorodeoxyglucose positron emission tomography in the parotid gland: a meta-analysis. Eur Arch Otorhinolaryngol. 2015;272(12):3617–26.
Nayan S, Ramakrishna J, Gupta MK. The proportion of malignancy in incidental thyroid lesions on 18-FDG PET study: a systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2014;151(2):190–200.
Treglia G, Bertagna F, Sadeghi R, Verburg FA, Ceriani L, Giovanella L. Focal thyroid incidental uptake detected by (1)(8)F-fluorodeoxyglucose positron emission tomography. Meta-analysis on prevalence and malignancy risk. Nuklearmedizin. 2013;52(4):130–6.
Shie P, Cardarelli R, Sprawls K, Fulda KG, Taur A. Systematic review: prevalence of malignant incidental thyroid nodules identified on fluorine-18 fluorodeoxyglucose positron emission tomography. Nucl Med Commun. 2009;30(9):742–8.
Bertagna F, Treglia G, Orlando E, Dognini L, Giovanella L, Sadeghi R, et al. Prevalence and clinical significance of incidental F18-FDG breast uptake: a systematic review and meta-analysis. Jpn J Radiol. 2014;32(2):59–68.
Benveniste AP, Marom EM, Benveniste MF, Mawlawi O, Fox PS, Yang W. Incidental primary breast cancer detected on PET-CT. Breast Cancer Res Treat. 2015;151(2):261–8.
Treglia G, Taralli S, Salsano M, Muoio B, Sadeghi R, Giovanella L. Prevalence and malignancy risk of focal colorectal incidental uptake detected by (18)F-FDG-PET or PET/CT: a meta-analysis. Radiol Oncol. 2014;48(2):99–104.
Adams SJ, Rakheja R, Bryce R, Babyn PS. Incidence and economic impact of incidental findings on (18)F-FDG PET/CT imaging. Can Assoc Radiol J. 2018;69(1):63–70.
MacMahon H, Naidich DP, Goo JM, Lee KS, Leung ANC, Mayo JR, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. Radiology. 2017;284(1):228–43.
Dong A, Cui Y, Wang Y, Zuo C, Bai Y. (18)F-FDG PET/CT of adrenal lesions. AJR Am J Roentgenol. 2014;203(2):245–52.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Oldan, J.D. (2021). Review of PET/CT Images in Melanoma and Sarcoma: False Positives, False Negatives, and Pitfalls. In: Khandani, A.H. (eds) PET/CT and PET/MR in Melanoma and Sarcoma. Springer, Cham. https://doi.org/10.1007/978-3-030-60429-5_5
Download citation
DOI: https://doi.org/10.1007/978-3-030-60429-5_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-60428-8
Online ISBN: 978-3-030-60429-5
eBook Packages: MedicineMedicine (R0)